分享产品介绍 评论(0)
物种
Human分子别名
CD309 antigen,CD309,EC 2.7.10,EC 2.7.10.1,Fetal liver kinase 1,fetal liver kinase-1,Flk1,Flk-1,soluble VEGFR2,vascular endothelial growth factor receptor 2,VEGF R2,VEGFR,VEGFR2,VEGFR-2Accession
P35968表达序列
Ala20-Glu764, with C-terminal 6*His表达宿主
HEK293分子量
100-130kDa (Reducing)纯度
＞95% by SDS-PAGE
内毒素含量
<0.1EU/μg标记
Unconjugated标签
His Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Vascular endothelial cell growth factor (VEGF) and VEGF receptor 2 (VEGF-R2) are closely related to angiogenesis in glioma. A number of phosphorylated sites, such as Y801, Y951, Y1175, and Y1214 in the VEGF-R2 intracellular domains mediate critical signal transductions, including PI3K/AKT, MAPK, and PKC pathways. Main functions of VEGF-R2 include increasing the expression of VEGF and inducing tumor angiogenesis. In addition, VEGF plays a role in promoting vascular endothelial cell division and angiogenesis through VEGF-R2 and is also involved in promoting the aggressive growth of tumors. In the kidney, VEGF is almost exclusively expressed in glomerular and tubular epithelial cells, while the VEGF-R2 is mainly present in glomerular and tubular endothelial cells, as well as in interstitial cells. The present study shows that VEGF-R2 overexpression in advanced thyroid cancer maintains cancer malignancy and cell survival. Thus, selective targeting of VEGFR2/KDR signaling may be a potential strategy for advanced thyroid cancer treatment.
电泳
- 1μg (R: reducing conditions, N: non-reducing conditions).
ELISA
Immobilized VEGF-121, Human (Cat. No. UA040082) at 2.0μg/mL (100μL/well) can bind VEGF-R2/KDR His Tag, Human (Cat. No. UA010164) with EC50 of 0.39-0.65μg/mL.
评论(0)